Neurocrine Biosciences, Inc.
NBIX
Positions held
Your positionsNBIX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Neurocrine Biosciences operates in a niche market with a strong focus on specialty drugs, positioning itself well against competitors in the healthcare sector.
- Revenue increased by 18% from the prior quarter, reaching $959 million.
- The company has a robust profit margin of 20.91%, indicating strong operational efficiency.
- The operating margin has compressed to 16%, which may raise concerns about cost management and profitability.
- The stock has a trailing P/E ratio of 21.34, suggesting it may be overvalued compared to industry peers.
- The current score is neutral at 3.00, indicating mixed market sentiment and potential volatility.
Fundamentals
| Market cap | $14.36B | Enterprise value | $14.43B | Trailing P/E | 20.71 | Forward P/E | 11.89 |
| PEG | 0.29 | Price / book | 3.89 | Beta | 0.40 | Dividend yield | 0.00% |
| Revenue growth | 39.5% | Earnings growth | 31.1% | Gross margin | 64.5% | Operating margin | 22.2% |
| Profit margin | 20.9% | ROE | 22.1% | ROA | 11.7% | Debt / equity | 0.12 |
| Current ratio | 1.87 | Free cash flow | $638.24M | Analyst recommendation | strong_buy | Mean target | $207.29 |
| 52w high | $186.12 | 52w low | $122.14 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $959M | $815M | $806M | $795M | $688M | — |
| Op margin | 16.0% | 22.8% | 28.3% | 30.1% | 21.2% | — |
| Net income | $144M | $198M | $154M | $210M | $108M | — |
| Gross margin | 97.6% | 98.3% | 97.8% | 98.2% | 98.5% | — |
| Gross profit | $936M | $801M | $788M | $781M | $677M | — |
| Operating income | $153M | $186M | $228M | $239M | $146M | — |
- Revenue +18% vs prior quarter ($959M vs $814M).
- Gross margin 97.6% (was 98.3% prior quarter).
- Operating margin compressed to 16%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.9B | $2.4B | $1.9B | $1.5B | — |
| Op margin | 22.3% | 24.8% | 20.9% | 16.7% | — |
| Net income | $479M | $341M | $250M | $155M | — |
| Gross margin | 98.2% | 98.6% | 97.9% | 98.4% | — |
| Gross profit | $2.8B | $2.3B | $1.8B | $1.5B | — |
| Operating income | $637M | $583M | $395M | $249M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-28 · Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer
2026-09-28 · Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
2026-09-23 · Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit
2026-09-21 · RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating
2026-09-18 · Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story
2026-09-08 · Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says
2026-09-02 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
2026-08-31 · Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
2026-08-28 · Neurocrine Biosciences (NBIX) Wins FDA Trial Nod, Is It Still Below Fair Value?
2026-08-27 · Did Nxera’s Alzheimer’s Milestone and IND Progress Just Shift Neurocrine Biosciences' (NBIX) Investment Narrative?
Price (daily)
Full chart · RSI · MACD · patterns